High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience.
Antman K, Eder JP, Elias A, Shea T, Peters WP, Andersen J, Schryber S, Henner WD, Finberg R, Wilmore D. High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience. Journal Of The National Cancer Institute 1987, 71: 119-25. PMID: 3542208.Peer-Reviewed Original ResearchConceptsVeno-occlusive diseaseEvaluable patientsBreast cancerPrior treatmentAutologous bone marrow supportDose-limiting toxic effectFatal veno-occlusive diseaseCourses of cyclophosphamideDose level 4Bone marrow supportGood partial responseHigh-dose combinationDose level 5Metastatic breast cancerThree-drug combinationPolymorphonuclear leukocyte countAddition of melphalanHighest dose levelToxic effectsMarrow reinfusionMarrow supportPreparative regimenMost patientsPartial responseTransfusion independence